Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

Women in STEM bring diverse perspectives that are especially valuable in rare disease research. These conditions are complex and require innovative thinking. Attention to detail, empathy, and ...

Even when promising clinical trials exist, and the FDA allows expanded access, rare disease patients like my granddaughter ...

Time is running out for Congress to vote to reauthorize a program that incentivizes pharmaceutical companies to develop and bring to market drugs and therapies for children with rare diseases. In the ...

Examining both genetics and epigenetics is crucial for understanding the underlying mechanisms behind disease development and progression. Scientists have determined that alterations to DNA ...

Rare diseases affect only a small number of people yet have become an attractive target for ASX healthcare companies. ... Read More The post ASX healthcare players focusing on rare diseases as ...

Researchers show that PTP1B inhibitors could be used to help treat symptoms of Alzheimer's disease, revealing a potential new therapeutic pathway.

SALT LAKE CITY, UTAH – Researchers at the University of Utah's Department of Psychiatry and Huntsman Mental Health Institute today published a paper introducing RiskPath, an open source software ...